Evidence map›Paper›PMID 39468599›Full record

ArticleOrphanet journal of rare diseases2024

Experiences of mothers of long-term surviving patients with cerebral adrenoleukodystrophy: a qualitative study.

Yuta Koto, Nozomi Hadano, Norio Sakai

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuta KotoFaculty of Nursing, Graduate School of Nursing, Kansai Medical University, 2-2-2 Shinmachi, Hirakata, Osaka, 573-1004, Japan. kotoy@hirakata.kmu.ac.jp.ORCID 0000-0003-4314-4955
Nozomi HadanoDepartment of Nursing, Faculty of Nursing, Shitennoji University, 3-2-1 Gakuenmae, Habikino, Osaka, 583-8501, Japan.
Norio SakaiCenter for Promoting Treatment of Intractable Diseases, ISEIKAI International General Hospital, 4-14 Minamiogimachi, Kita-ku, Osaka, 530-0052, Japan.

Funding

JSPS KAKENHI JP22K17513
6 · The paper itself

Abstract

backgroundAdrenoleukodystrophy (ALD) is an X-linked peroxisomal disorder. Its cerebral form presents as a learning and behavioral disorder that, if untreated, leads to rapid neurological regression, disability, and death within 10 years of diagnosis. Therefore, the disease significantly impacts patients' quality of life, making quality of life assessment crucial for effective medical treatment and care. However, no disease-specific quality of life scale exists for ALD. Therefore, we conducted qualitative research to determine the experiences of patients and their families as a preliminary step toward developing one.

resultsFour mothers of patients with cerebral ALD were interviewed. Based on classification using the qualitative content analysis method, the verbatim transcripts were grouped into four themes: support needs for patients, support needs for families, the impact of treatment, and challenges within support systems.

conclusionsSupport for patients and family members is required after ALD is diagnosed. In addition to addressing symptoms, daily life support and caregiving burden should be considered. Furthermore, several challenges and opportunities exist for improving treatment and support systems. Therefore, combining appropriate supporters and support systems according to the progressive and hereditary characteristics of ALD is crucial.

Indexed as

AdrenoleukodystrophyMothersQualitative ResearchQuality of LifeAdultFemaleHumansMaleMiddle AgedAdrenoleukodystrophyCaregiver burdenHematopoietic stem cell transplantationQuality of lifeSiblings

Identifiers

PMID39468599
PMCPMC11520452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.